GINA 2021 Asthma

Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes

The document that ended fifty years of short-acting beta agonist monotherapy. GINA no longer recommends a reliever inhaler alone at any step of asthma treatment: every adult and adolescent should carry an inhaled corticosteroid, either in the reliever itself as budesonide-formoterol taken as needed, or as a daily controller alongside a separate reliever. The reasoning is that a patient who feels better after a puff of salbutamol has treated the symptom and not the inflammation, and that the risk of a severe exacerbation, and of death, tracks reliever use. Track 1, with as-needed budesonide-formoterol, is named the preferred approach because it is the one that reduces severe exacerbations without asking a well-feeling patient to take a daily drug. The register's trials behind that reversal are below.

Esta norma cita 2 dos 35 ensaios marcantes do nosso registo de Pneumologia.

Fonte
Reddel HK, Bacharier LB, Bateman ED, et al. Eur Respir J. 2021;59(1):2102730. · European Respiratory Journal

As-needed budesonide-formoterol2

  • 2018SYGMA 1Pneumo · Asma · CIE-formoterol em SOSEm 3.849 doentes com asma ligeira, o budesonido-formoterol em SOS reduziu as exacerbações graves em comparação com terbutalina em SOS.
  • 2018SYGMA 2Pneumo · Asma · CIE-formoterol em SOSEm 4.215 doentes com asma ligeira, o budesonido-formoterol em SOS foi não-inferior relativamente a exacerbações graves em comparação com budesonido de manutenção diário mais terbutalina em SOS.